Required B.Sc as Manucturing Executive at Mintgomery Agencies
We deal in distribution business of fmcg goods in Haridwar city and planning to manufacture Phenyle.
Post: Manucturing Executive
(7th September, 2014); India and Australia are exploring cooperation possibilities in preventive healthcare, trauma care, geriatric medicine, diabetes research and mental illnesses. This found iteration in the dialogue held between the visiting Prime Minister of Australia, Mr Tony Abbott, and the Union Health Minister, Dr Harsh Vardhan, on 5th Sept, Friday.
(5th September, 2014; Business Wire India); “India & Japan have a big opportunity of working together in the area of healthcare. Japan has achieved its goal of longevity and healthy life for all its citizens. This knowledge and technology will benefit India as well as the rest of the world. Shri Narendra Modi, Hon’ble Prime Minister of India, has already extended an open invitation to COME MAKE IN INDIA. India will give Japan a huge consuming population, excellent human resources and a low cost base for manufacturing and exporting healthcare solutions to the world”, said Rajesh Srivastava, Chairman, Rockland Hospitals. He was speaking on the topic: Creating Healthcare Access for Cancer Treatment: Sharing Japanese Solutions, during a two days seminar titled FICCI- Heal-2014 on 1 & 2 Sept in Delhi.
(4th September, 2014); Florida Scientists from The Scripps Research Institute (TSRI) have considered chemical approach to convert diseased cells to be manufacturing site of a molecule which can treat muscular dystrophy. The promising research was published recently in the international chemistry journal Angewandte Chemie.
(3rd September, 2014); The news in July that HIV had returned in a Mississippi toddler after a two-year treatment-free remission dashed the hopes of clinicians, HIV researchers and the public at large tantalized by the possibility of a cure. But a new commentary by two leading HIV experts at Johns Hopkins argues that despite its disappointing outcome, the Mississippi case and two other recent HIV "rebounds" in adults, have yielded critical lessons about the virus' most perplexing - and maddening - feature: its ability to form cure-defying viral hideouts.
(3rd September, 2014); The new agent, an angiotensin receptor-neprilysin inhibitor (ARNI) known as LCZ696, has already been granted Fast Track status by the United States Food and Drug Administration (FDA) – a designation which can expedite the review of new medicines intended to treat serious or life-threatening conditions. And surprisingly, LCZ696 was superior to ACE-inhibitor, enalapril, on key endpoints in the largest heart failure study ever done.